Global Multiple Sclerosis Market, Patient Numbers & Forecast By Mode of Administration – Actual & Unmet (Potential)
Global Multiple Sclerosis Market, Patient Numbers & Forecast (By Mode of Administration: Injectables Market, Infusions Market, Orals Market) – Actual & Unmet (Potential) published by Renub Research on Multiple Sclerosis Market.
Get Free 10% Customization in This Report
Global multiple sclerosis market is steadily growing and it is expected to cross over US$ 20 Billion landmark by 2022. Multiple sclerosis market is one of the most common neurological disorder diseases in the world. It is estimated that global multiple sclerosis patient numbers will increase around 35 Thousand by 2022. According to Renub Research analysis, we have found that there is huge gap between actual and unmet market as disease modifying therapy receiving prevalence vary from country to country. Global multiple sclerosis unmet market is much higher compared to its actual market.
Request a free sample copy of the report: http://www.renub.com/contactus.php
Reimbursement is key growth driver for Multiple Sclerosis market globally
Reimbursement is playing major role for the growth of multiple sclerosis market as multiple sclerosis drugs are too expensive and without reimbursement, it is nearly impossible to afford the treatment of MS by most of the multiple sclerosis patient in the world. Most of the European and North American countries have multiple sclerosis reimbursement policy; however eligibility criteria vary from country to country.
Multiple Sclerosis Drugs price is too expensive
Multiple sclerosis drugs price is steadily increasing which create a major challenge for the growth of multiple sclerosis market in the world. It is estimated that newly launched multiple sclerosis drugs are expensive than previous generation disease modifying drugs. According to our research, we have found that, United States multiple sclerosis drugs are nearly five times higher than European multiple sclerosis drugs price.
Injectables Disease Modifying Therapy Multiple Sclerosis Market is losing Ground
Injectables disease modifying therapy multiple sclerosis market is continuously declining. Newly launched orals disease modifying therapy is a growing market.
This 108 page report with 93 figures and 1 Tables provides 6 Countries: actual and potential/unmet patient numbers and market. This report also explains multiple sclerosis disease modifying therapy (DMT) mode of administration.
• Actual Market is the current market which is already present
• Unmet Market is the market which can be accomplished; but it has yet not been accomplished due to demand and supply gap. At present DMT receiving patients are less than total number of multiple sclerosis patient numbers.
6 Countries Multiple Sclerosis Market & Patients Treated Studied in the Report is as Follows:
1. United States
2. United Kingdom
3. Germany
4. France
5. Italy
6. Spain
Worldwide and United States Multiple Sclerosis Market & Patients Treated by Mode of administration
1. Injectables
2. Infusions
3. Orals
Key Questions Answered in the Report?
• What is multiple sclerosis market globally and its growth potential in Future?
• How many number of patients treated by disease modifying therapy globally?
• What is the multiple sclerosis market in United States and other European countries?
• How many number of multiple sclerosis patients living in United States and other European countries?
1. Research Findings
2. Global Multiple Sclerosis Patient Numbers (2011 – 2022)
2.1 Patient Number & Forecast
2.2 Disease-Modifying Therapy (DMT) Patient Numbers & Forecast
2.3 By Mode of Administration – Injectables, Infusion, Oral Patient Numbers & Forecast
2.3.1 Injectables
2.3.2 Infusions
2.3.3 Orals
3. Global Multiple Sclerosis Market (2011 – 2022)
3.1 Unmet Market & Forecast
3.2 Market & Forecast
3.3 By Mode of Administration - Injectables, Infusions, Orals Market & Forecast
3.3.1 Injectables Market
3.3.2 Infusions Market
3.3.3 Orals Market
4. Patient Share – Global Multiple Sclerosis (2011 – 2022)
4.1 Patient Numbers Share & Forecast – (UK, France, Germany, Italy, Spain & United States)
4.2 Disease-Modifying Therapy (DMT) – (UK, France, Germany, Italy, Spain & United States)
4.3 By Mode of Administration – Injectables, Infusion, Oral
5. Market Share – Global Multiple Sclerosis (2011 – 2022)
5.1 Unmet Market Share & Forecast – (UK, France, Germany, Italy, Spain & United States)
5.2 Market Share & Forecast – (UK, France, Germany, Italy, Spain & United States)
5.3 By Mode of Administration – Injectables, Infusion, Oral
6. United Kingdom
6.1 Multiple Sclerosis Patient Numbers (2011 – 2022)
6.1.1 Patient Number & Forecast
6.1.2 Disease-Modifying Therapy (DMT) Patient Numbers & Forecast
6.2 Multiple Sclerosis Market (2011 – 2022)
6.2.1 Unmet Market & Forecast
6.2.2 Market & Forecast
7. France
7.1 Multiple Sclerosis Patient Number (2011 – 2022)
7.1.1 Patient Number & Forecast
7.1.2 Disease-Modifying Therapy (DMT) Patient Numbers & Forecast
7.2 Multiple Sclerosis Market (2011 – 2022)
7.2.1 Unmet Market & Forecast
7.2.2 Market & Forecast
8. Germany
8.1 Multiple Sclerosis Patient Number (2011 – 2022)
8.1.1 Patient Number & Forecast
8.1.2 Disease-Modifying Therapy (DMT) Patient Numbers & Forecast
8.2 Multiple Sclerosis Market (2011 – 2022)
8.2.1 Unmet Market & Forecast
8.2.2 Market & Forecast
9. Italy
9.1 Multiple Sclerosis Patient Number (2011 – 2022)
9.1.1 Patient Number & Forecast
9.1.2 Disease-Modifying Therapy (DMT) Patient Numbers & Forecast
9.2 Multiple Sclerosis Market (2011 – 2022)
9.2.1 Unmet Market & Forecast
9.2.2 Market & Forecast
10. Spain
10.1 Multiple Sclerosis Patient Number (2011 – 2022)
10.1.1 Patient Number & Forecast
10.1.2 Disease-Modifying Therapy (DMT) Patient Numbers & Forecast
10.2 Multiple Sclerosis Market (2011 – 2022)
10.2.1 Unmet Market & Forecast
10.2.2 Market & Forecast
11. United States
11.1 Multiple Sclerosis Patient Numbers (2011 – 2022)
11.1.1 Patient Number & Forecast
11.1.2 Disease-Modifying Therapy (DMT) Patient Numbers & Forecast
11.2 By Mode of Administration
11.2.1 Injectables Patients Numbers
11.2.2 Infusions Patients Numbers
11.2.3 Orals Patient Numbers
11.3 United States Multiple Sclerosis Market (2011 – 2022)
11.3.1 Unmet Market & Forecast
11.3.2 Market & Forecast
11.4 By Mode of Administration
11.4.1 Injectables Market
11.4.2 Infusions Market
11.4.3 Orals Market
12. Growth Drivers (Due to data confidentiality, growth factors have not been disclosed in this table of contents)
12.1 Point no. 1
12.2 Point no. 2
13. Challenges (Due to data confidentiality, challenges have not been disclosed in this table of contents)
13.1 Point no. 1
13.2 Point no. 2
13.3 Point no. 3
14. Appendix
List of Figures
Figure 2‑1: Global - Multiple Sclerosis Patient Numbers (Thousand), 2011 - 2016
Figure 2‑2: Global – Forecast for Multiple Sclerosis Patient Numbers (Thousand), 2017 - 2022
Figure 2‑3: Global - Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2011 - 2016
Figure 2‑4: Global – Forecast for Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2017 - 2022
Figure 2‑5: Global – Multiple Sclerosis Injectables Patient Numbers (Thousand), 2011 – 2016
Figure 2‑6: Global – Forecast for Multiple Sclerosis Injectables Patient Numbers (Thousand), 2017 – 2022
Figure 2‑7: Global - Multiple Sclerosis Infusions Patient Numbers (Thousand), 2011 – 2016
Figure 2‑8: Global – Forecast for Multiple Sclerosis Infusions Patient Numbers (Thousand), 2017 – 2022
Figure 2‑9: Global - Multiple Sclerosis Orals Patient Numbers (Thousand), 2011 – 2016
Figure 2‑10: Global – Forecast for Multiple Sclerosis Orals Patient Numbers (Thousand), 2017 – 2022
Figure 3‑1: Global – Multiple Sclerosis Unmet Market (Billion US$), 2011 – 2016
Figure 3‑2: Global – Forecast for Multiple Sclerosis Unmet Market (Billion US$), 2017 – 2022
Figure 3‑3: Global – Multiple Sclerosis Market (Billion US$), 2011 – 2016
Figure 3‑4: Global – Forecast for Multiple Sclerosis Market (Billion US$), 2017 – 2022
Figure 3‑5: Global – Multiple Sclerosis Injectables Market (Million US$), 2011 – 2016
Figure 3‑6: Global – Forecast for Multiple Sclerosis Injectables Market (Million US$), 2017 – 2022
Figure 3‑7: Global – Multiple Sclerosis Infusions Market (Million US$), 2011 – 2016
Figure 3‑8: Global – Forecast for Multiple Sclerosis Infusions Market (Million US$), 2017 – 2022
Figure 3‑9: Global – Multiple Sclerosis Orals Market (Million US$), 2011 – 2016
Figure 3‑10: Global – Forecast for Multiple Sclerosis Orals Market (Million US$), 2017 – 2022
Figure 4‑1: Global - Patient Numbers Share (Percent), 2011 – 2016
Figure 4‑2: Global – Forecast for Patient Numbers Share (Percent), 2017 – 2022
Figure 4‑3: Global - Disease-Modifying Therapy (DMT) Patient Numbers Share (Percent), 2011 – 2016
Figure 4‑4: Global – Forecast for Disease-Modifying Therapy (DMT) Patient Numbers Share (Percent), 2017 – 2022
Figure 4‑5: Global – Multiple Sclerosis Mode of Administration Patient Numbers Share (Percent), 2011 – 2016
Figure 4‑6: Global – Forecast for Multiple Sclerosis Mode of Administration Patient Numbers Share (Percent), 2017 – 2022
Figure 4‑7: Global – Multiple Sclerosis Unmet Market Share (Percent), 2011 – 2016
Figure 4‑8: Global – Forecast for Multiple Sclerosis Unmet Market Share (Percent), 2017 – 2022
Figure 4‑9: Global – Multiple Sclerosis Market Share (Percent), 2011 – 2016
Figure 4‑10: Global – Forecast for Multiple Sclerosis Market Share (Percent), 2017 – 2022
Figure 4‑11: Global – Multiple Sclerosis Market by Mode of Administration Share (Percent), 2011 – 2016
Figure 4‑12: Global – Forecast for Multiple Sclerosis Market by Mode of Administration Share (Percent), 2017 – 2022
Figure 5‑1: United Kingdom – Multiple Sclerosis Patient Numbers (Thousand), 2011 – 2016
Figure 5‑2: United Kingdom – Forecast for Multiple Sclerosis Patient Numbers (Thousand), 2017 – 2022
Figure 5‑3: United Kingdom – Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2011 – 2016
Figure 5‑4: United Kingdom – Forecast for Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2017 – 2022
Figure 5‑5: United Kingdom – Multiple Sclerosis Unmet Market (Million US$), 2011 – 2016
Figure 5‑6: United Kingdom – Forecast for Multiple Sclerosis Unmet Market (Million US$), 2017 – 2022
Figure 5‑7: United Kingdom – Multiple Sclerosis Market (Million US$), 2011 – 2016
Figure 5‑8: United Kingdom – Forecast for Multiple Sclerosis Market (Million US$), 2017 – 2022
Figure 6‑1: France – Multiple Sclerosis Patient Numbers (Thousand), 2011 – 2016
Figure 6‑2: France – Forecast for Multiple Sclerosis Patient Numbers (Thousand), 2017 – 2022
Figure 6‑3: France – Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2011 – 2016
Figure 6‑4: France – Forecast for Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2017 – 2022
Figure 6‑5: France – Multiple Sclerosis Unmet Market (Million US$), 2011 – 2016
Figure 6‑6: France – Forecast for Multiple Sclerosis Unmet Market (Million US$), 2017 – 2022
Figure 6‑7: France – Multiple Sclerosis Market (Million US$), 2011 – 2016
Figure 6‑8: France – Forecast for Multiple Sclerosis Market (Million US$), 2017 – 2022
Figure 7‑1: Germany – Multiple Sclerosis Patient Numbers (Thousand), 2011 – 2016
Figure 7‑2: Germany – Forecast for Multiple Sclerosis Patient Numbers (Thousand), 2017 – 2022
Figure 7‑3: Germany – Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2011 – 2016
Figure 7‑4: Germany – Forecast for Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2017 – 2022
Figure 7‑5: Germany – Multiple Sclerosis Unmet Market (Million US$), 2011 – 2016
Figure 7‑6: Germany – Forecast for Multiple Sclerosis Unmet Market (Million US$), 2017 – 2022
Figure 7‑7: Germany – Multiple Sclerosis Market (Million US$), 2011 – 2016
Figure 7‑8: Germany – Forecast for Multiple Sclerosis Market (Million US$), 2017 – 2022
Figure 8‑1: Italy – Multiple Sclerosis Patient Numbers (Thousand), 2011 – 2016
Figure 8‑2: Italy – Forecast for Multiple Sclerosis Patient Numbers (Thousand), 2017 – 2022
Figure 8‑3: Italy – Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2011 – 2016
Figure 8‑4: Italy – Forecast for Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2017 – 2022
Figure 8‑5: Italy – Multiple Sclerosis Unmet Market (Million US$), 2011 – 2016
Figure 8‑6: Italy – Forecast for Multiple Sclerosis Unmet Market (Million US$), 2017 – 2022
Figure 8‑7: Italy – Multiple Sclerosis Market (Million US$), 2011 – 2016
Figure 8‑8: Italy – Forecast for Multiple Sclerosis Market (Million US$), 2017 – 2022
Figure 9‑1: Spain – Multiple Sclerosis Patient Numbers (Thousand), 2011 – 2016
Figure 9‑2: Spain – Forecast for Multiple Sclerosis Patient Numbers (Thousand), 2017 – 2022
Figure 9‑3: Spain – Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2011 – 2016
Figure 9‑4: Spain – Forecast for Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2017 – 2022
Figure 9‑5: Spain – Multiple Sclerosis Unmet Market (Million US$), 2011 – 2016
Figure 9‑6: Spain – Forecast for Multiple Sclerosis Unmet Market (Million US$), 2017 – 2022
Figure 9‑7: Spain – Multiple Sclerosis Market (Million US$), 2011 – 2016
Figure 9‑8: Spain – Forecast for Multiple Sclerosis Market (Million US$), 2017 – 2022
Figure 10‑1: United States – Multiple Sclerosis Patient Numbers (Thousand), 2011 – 2016
Figure 10‑2: United States – Forecast for Multiple Sclerosis Patient Numbers (Thousand), 2017 – 2022
Figure 10‑3: United States – Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2011 – 2016
Figure 10‑4: United States – Forecast for Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2017 – 2022
Figure 10‑5: United States – Multiple Sclerosis Injectables Patient Numbers (Thousand), 2011 – 2016
Figure 10‑6: United States – Forecast for Multiple Sclerosis Injectables Patient Numbers (Thousand), 2017 – 2022
Figure 10‑7: United States - Multiple Sclerosis Infusions Patient Numbers (Thousand), 2011 – 2016
Figure 10‑8: United States – Forecast for Multiple Sclerosis Infusions Patient Numbers (Thousand), 2017 – 2022
Figure 10‑9: United States - Multiple Sclerosis Orals Patient Numbers (Thousand), 2011 – 2016
Figure 10‑10: United States – Forecast for Multiple Sclerosis Orals Patient Numbers (Thousand), 2017 – 2022
Figure 10‑11: United States – Multiple Sclerosis Unmet Market (Billion US$), 2011 – 2016
Figure 10‑12: United States – Forecast for Multiple Sclerosis Unmet Market (Billion US$), 2017 – 2022
Figure 10‑13: United States – Multiple Sclerosis Market (Billion US$), 2011 – 2016
Figure 10‑14: United States – Forecast for Multiple Sclerosis Market (Billion US$), 2017 – 2022
Figure 10‑15: United States – Multiple Sclerosis Injectables Market (Million US$), 2011 – 2016
Figure 10‑16: United States – Forecast for Multiple Sclerosis Injectables Market (Million US$), 2017 – 2022
Figure 10‑17: United States – Multiple Sclerosis Infusions Market (Million US$), 2011 – 2016
Figure 10‑18: United States – Forecast for Multiple Sclerosis Infusions Market (Million US$), 2017 – 2022
Figure 10‑19: United States – Multiple Sclerosis Orals Market (Million US$), 2011 – 2016
Figure 10‑20: United States – Forecast for Multiple Sclerosis Orals Market (Million US$), 2017 – 2022
Figure 12‑1: Europe - Number of Neurologists per 100,000 Specialized in MS vs. Percent of MS Population Receiving DMDs, 2013
List of Tables
Table 11 1: Europe - Reimbursements for Disease Modifying Drugs (DMDs), 2013
Reach out to us
Call us on
USA: +1-678-302-0700
INDIA: +91-120-421-9822
Drop us an email at
info@renub.com